|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OSGIN2 |
Gene summary for OSGIN2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OSGIN2 | Gene ID | 734 |
| Gene name | oxidative stress induced growth inhibitor family member 2 | |
| Gene Alias | C8orf1 | |
| Cytomap | 8q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9Y236 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 734 | OSGIN2 | LZE24T | Human | Esophagus | ESCC | 2.80e-07 | 3.05e-02 | 0.0596 |
| 734 | OSGIN2 | P2T-E | Human | Esophagus | ESCC | 5.52e-15 | 3.31e-02 | 0.1177 |
| 734 | OSGIN2 | P4T-E | Human | Esophagus | ESCC | 1.03e-09 | 2.18e-01 | 0.1323 |
| 734 | OSGIN2 | P5T-E | Human | Esophagus | ESCC | 5.11e-07 | 1.92e-02 | 0.1327 |
| 734 | OSGIN2 | P8T-E | Human | Esophagus | ESCC | 3.49e-12 | 1.11e-01 | 0.0889 |
| 734 | OSGIN2 | P9T-E | Human | Esophagus | ESCC | 5.60e-06 | 7.15e-02 | 0.1131 |
| 734 | OSGIN2 | P10T-E | Human | Esophagus | ESCC | 3.31e-18 | 5.63e-02 | 0.116 |
| 734 | OSGIN2 | P12T-E | Human | Esophagus | ESCC | 1.89e-13 | 5.20e-02 | 0.1122 |
| 734 | OSGIN2 | P15T-E | Human | Esophagus | ESCC | 1.65e-04 | 1.49e-03 | 0.1149 |
| 734 | OSGIN2 | P16T-E | Human | Esophagus | ESCC | 3.44e-11 | 4.58e-02 | 0.1153 |
| 734 | OSGIN2 | P17T-E | Human | Esophagus | ESCC | 8.00e-03 | 9.27e-02 | 0.1278 |
| 734 | OSGIN2 | P20T-E | Human | Esophagus | ESCC | 1.74e-03 | -2.75e-03 | 0.1124 |
| 734 | OSGIN2 | P21T-E | Human | Esophagus | ESCC | 3.44e-16 | 1.59e-01 | 0.1617 |
| 734 | OSGIN2 | P22T-E | Human | Esophagus | ESCC | 7.37e-15 | 8.00e-02 | 0.1236 |
| 734 | OSGIN2 | P23T-E | Human | Esophagus | ESCC | 4.88e-05 | 1.02e-01 | 0.108 |
| 734 | OSGIN2 | P24T-E | Human | Esophagus | ESCC | 1.17e-09 | 4.85e-02 | 0.1287 |
| 734 | OSGIN2 | P26T-E | Human | Esophagus | ESCC | 7.95e-06 | 1.72e-01 | 0.1276 |
| 734 | OSGIN2 | P27T-E | Human | Esophagus | ESCC | 8.91e-08 | 2.45e-02 | 0.1055 |
| 734 | OSGIN2 | P28T-E | Human | Esophagus | ESCC | 3.46e-22 | 2.36e-01 | 0.1149 |
| 734 | OSGIN2 | P30T-E | Human | Esophagus | ESCC | 1.86e-08 | 3.06e-01 | 0.137 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
| GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
| GO:00459267 | Esophagus | ESCC | negative regulation of growth | 148/8552 | 249/18723 | 7.88e-06 | 7.73e-05 | 148 |
| GO:00303085 | Esophagus | ESCC | negative regulation of cell growth | 108/8552 | 188/18723 | 7.46e-04 | 3.87e-03 | 108 |
| GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
| GO:000155821 | Liver | HCC | regulation of cell growth | 228/7958 | 414/18723 | 1.34e-07 | 2.55e-06 | 228 |
| GO:00459263 | Liver | HCC | negative regulation of growth | 129/7958 | 249/18723 | 1.81e-03 | 9.37e-03 | 129 |
| GO:0030308 | Liver | HCC | negative regulation of cell growth | 98/7958 | 188/18723 | 4.74e-03 | 2.02e-02 | 98 |
| GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
| GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
| GO:00459266 | Oral cavity | OSCC | negative regulation of growth | 135/7305 | 249/18723 | 7.29e-07 | 1.03e-05 | 135 |
| GO:00303084 | Oral cavity | OSCC | negative regulation of cell growth | 101/7305 | 188/18723 | 2.85e-05 | 2.63e-04 | 101 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OSGIN2 | SNV | Missense_Mutation | novel | c.1229N>A | p.Ser410Tyr | p.S410Y | Q9Y236 | protein_coding | deleterious(0.01) | possibly_damaging(0.446) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OSGIN2 | insertion | Frame_Shift_Ins | novel | c.1600_1601insTTAGGATG | p.Lys534IlefsTer18 | p.K534Ifs*18 | Q9Y236 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| OSGIN2 | SNV | Missense_Mutation | c.991G>C | p.Glu331Gln | p.E331Q | Q9Y236 | protein_coding | tolerated(0.23) | possibly_damaging(0.843) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| OSGIN2 | SNV | Missense_Mutation | novel | c.1220N>G | p.Gln407Arg | p.Q407R | Q9Y236 | protein_coding | tolerated(0.08) | possibly_damaging(0.595) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| OSGIN2 | SNV | Missense_Mutation | rs780270897 | c.1025G>A | p.Arg342His | p.R342H | Q9Y236 | protein_coding | tolerated(0.27) | benign(0.001) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| OSGIN2 | SNV | Missense_Mutation | c.793A>C | p.Lys265Gln | p.K265Q | Q9Y236 | protein_coding | tolerated(0.68) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| OSGIN2 | SNV | Missense_Mutation | novel | c.75G>T | p.Glu25Asp | p.E25D | Q9Y236 | protein_coding | tolerated_low_confidence(0.22) | benign(0.012) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| OSGIN2 | SNV | Missense_Mutation | rs533674331 | c.1024C>T | p.Arg342Cys | p.R342C | Q9Y236 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OSGIN2 | SNV | Missense_Mutation | c.872N>A | p.Ser291Tyr | p.S291Y | Q9Y236 | protein_coding | deleterious(0.01) | possibly_damaging(0.7) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| OSGIN2 | SNV | Missense_Mutation | c.628N>G | p.Lys210Glu | p.K210E | Q9Y236 | protein_coding | tolerated(0.1) | possibly_damaging(0.501) | TCGA-AF-3913-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | xeloda | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |